Curigin

Curigin is a South Korean biotechnology company specializing in the development of next-generation oncolytic virus therapies integrated with RNA interference technology. The company's core platform utilizes modified adenoviruses to deliver short hairpin RNA (shRNA) directly into tumor cells, enabling a dual-action approach that combines viral-mediated cell lysis with the silencing of critical oncogenic genes. Their lead clinical candidate, CG103, targets the mTOR and STAT3 pathways and is currently being evaluated in clinical trials for the treatment of bladder cancer. Beyond its lead program, Curigin is advancing a diverse pipeline of candidates for various solid tumors, including prostate and lung cancers. By addressing the complexities of the tumor microenvironment, Curigin aims to overcome resistance mechanisms and improve outcomes for patients with advanced malignancies. The company's innovative approach has attracted significant investment from major Korean venture capital firms, supporting its expansion into global clinical development.